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OBJECTIVE: The cytokine interleukin-22 (IL-22), which is produced by T cells and natural killer cells, is associated
with tumorigenesis and tumor progression in cancers. However, the role of IL-22 in bladder cancer has not been
investigated.
MATERIALS AND METHODS: A prospective hospital-based case-control study comprising 210 patients with
pathologically proven bladder cancer and 210 age- and gender-matched healthy controls was conducted. The
genotypes of 3 common polymorphisms (-429 C/T, +1046 T/A and +1995 A/C) of the IL-22 gene were
determined with fluorogenic 5’ exonuclease assays.
RESULTS: Patients with bladder cancer had a significantly higher frequency of the IL-22 -429 TT genotype [odds
ratio (OR)=2.04, 95% confidence interval (CI)=1.19, 3.49; p=0.009] and -429 T allele (OR=1.42, 95% CI=1.08, 1.87;
p=0.01) than the healthy controls. These findings were still significant after a Bonferroni correction. When
stratifying according to the stage of bladder cancer, we found that patients with superficial bladder cancer had
a significantly lower frequency of the IL-22 -429 TT genotype (OR=0.48, 95% CI=0.23, 0.98; p=0.04). When
stratifying according to the grade and histological type of bladder cancer, we found no statistical association.
The IL-22 +1046 T/A and IL-22 +1995 A/C gene polymorphisms were not associated with the risk of bladder
cancer.
CONCLUSION: To the authors’ knowledge, this is the first report documenting that the IL-22 -429 C/T gene
polymorphism is associated with bladder cancer risk. Additional studies are required to confirm this finding.
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Bladder cancer is the most common cancer of the urinary tract
and is the fourth most commonly diagnosed malignancy in men
in the United States. It is estimated that 74,000 new cases of
bladder cancer are expected to occur in the United States in 2015
(1). Smoking tobacco and occupational exposure to chemical
carcinogens have been established as the strongest risk factors
for developing bladder cancer (2-4). It is now commonly
accepted that the cause of bladder cancer is the multi-factorial
interaction of environmental triggers with genetic susceptibility
(5-9). Genome-wide association studies have identified multiple
susceptibility loci associated with bladder cancer risk (10-13).
Interleukin-22 (IL-22) is a member of the IL-10 family or
IL-10 superfamily, a class of potent mediators of cellular
inflammatory responses (14). IL-22 is synthesized by
different cell types, including T- and natural killer (NK)-cells
and has been reported to mediate crosstalk between
inflammatory cells and keratinocytes (15-17). IL-22 is also
associated with tumorigenesis and tumor progression in
cancers (18,19). The human IL-22 gene is located on the long
arm of chromosome 12, on 12q15, approximately 52 and 99
kbp upstream from the IL-26 and interferon loci, respectively
and has the same transcriptional orientation as these two
adjoining genes (15). Several single nucleotide polymorph-
isms (SNPs) have previously been identified in the IL-22 gene
(20-27).
However, the role of IL-22 in bladder cancer has not been
investigated. The aim of this study was to investigate the
association between IL-22 gene polymorphisms (-429 C/T,
+1046 T/A and+1995 A/C) and the risk of bladder cancer
in a Chinese population.
’ MATERIALS AND METHODS
Study population
A prospective hospital-based case-control study of 210
patients with pathologically proven bladder cancer and 210DOI: 10.6061/clinics/2015(10)05
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age- and gender-matched healthy controls was conducted in
the Department of Urology of the YongChuan Hospital of
ChongQing Medical University. The healthy control subjects
were randomly selected when they attended a clinic for a
routine examination. All the bladder cancer cases were
staged according to the TNM staging system of the Union
Internationale Contre le Cancer. Bladder tumors were graded
using the World Health Organization (WHO) classification.
All the individuals were interviewed by trained nurse-
interviewers using a structured questionnaire that asked for
information regarding the patients’ gender, age, smoking
status and occupational and other exposure histories. All
parts of the study were approved by the Institutional Ethical
Committee of the ChongQing Medical University and
informed consent according to the Declaration of Helsinki
was obtained from all the participants or their families/
surrogates.
DNA extraction and genotyping
DNA was extracted from peripheral blood lymphocytes
using a commercially available Qiagen kit (Qiagen Inc.,
Valencia, CA, USA). The genotypes of 3 common poly-
morphisms (-429 C/T, +1046 T/A and +1995 A/C) of the
IL-22 gene were determined with fluorogenic 5’ exonuclease
assays (TaqMan, Applied Biosystems, Foster City, CA, USA).
The primer and probe sequences for the 5’-exonuclease
assays of the IL-22 polymorphisms are listed in Table 1. The
polymerase chain reaction (PCR) was performed in a Primus
96 plus thermal cycler using a total volume of 5 ml containing
2.5 ml of Universal-MasterMix, 0.125 ml of 40x Assay-by-
Design mix, 0.375 ml of H2O and 2 ml of DNA. The reactions
were overlaid with 15 ml of mineral oil. The cycling
parameters were as follows: 10 min at 94oC for primary
denaturation, followed by 40 cycles of 20 s at 92oC and 1 min
at 60oC. Fluorescence was measured in a Lambda Fluoro 320
Plus plate reader (MWG Biotech AG, Germany).
Statistical analysis
The data were presented as the means±standard devia-
tion (SD) or as percentages for categorical variables.
Differences between continuous variables were assessed
using Student’s t test, while those between categorical
variables were evaluated using Pearson’s x2 test. A multi-
variate logistic regression analysis was used to calculate
crude and adjusted odds ratios (OR) and 95% confidence
intervals (CI) for the association between each IL-22
polymorphism and bladder cancer risk. Statistical significance
Table 1 - Primer and probe sequences for the 5’-exonuclease assays of IL-22 polymorphisms.
SNPs rs2227485 rs1182844 rs1179246
Exchange -429 C/T +1046 T/A +1995 A/C
Forward Primer AAAATGAGTCCGTGACCAAAATGC CCACCTATGAGACTTCCCTATCAGT GAAAAAGCCTTCCTGCCTAATGG
Reverse Primer ACACAATTGTTTTGTCTTAGTAGAGTTCAGAT CACTAAAGGAAAAGGAAAGCTGTGTTT GGTGCTGCCTAAAGGTCAGA
Wild-type Probe FAM-CTCCTATAGTGACTGAGTAA-NFQ VIC-AAACTTACTAGTAGGTATGACTC-NFQ VIC-TGAACAGAGTTATCTGCCTC-NFQ
Mutant Probe VIC-CTCCTATAGTGGCTGAGTAA-NFQ FAM-CTTACTAGTAGGAATGACTC-NFQ FAM-AACAGAGTTAGCTGCCTC-NFQ
SNPs: single nucleotide polymorphisms.
Table 2 - Distribution of the characteristics of bladder cancer






Sex (Male/Female) 134/76 127/83 0.48
Age (Years) 61.3±9.8 60.7±9.4 0.52







Tumor histological type (%)
Papillary 157(74.8)
Nonpapillary 53(25.2)
Table 3 - Genotype and allele frequencies of IL-22 gene polymorphisms among bladder cancer cases and healthy controls.
Genotypes Cases (n=210) Controls (n=210) OR (95% CI) p
-429 CC 68(32.4) 79(37.6) 1.00(Reference)
-429 CT 84(40.0) 98(46.7) 1.00(0.64,1.54) 0.99
-429 TT 58(27.6) 33(15.7) 2.04(1.19,3.49) 0.009
-429 C allele frequency 220(52.4) 256(60.9) 1.00(Reference)
-429 T allele frequency 200(47.6) 164(39.1) 1.42(1.08,1.87) 0.01
+1046 TT 90(42.8) 97(46.2) 1.00(Reference)
+1046 TA 77(36.7) 74(35.2) 1.12(0.73,1.72) 0.60
+1046 AA 43(20.5) 39(18.6) 1.19(0.71,2.00) 0.52
+1046 T allele frequency 257(61.2) 268(63.8) 1.00(Reference)
+1046 A allele frequency 163(38.8) 152(36.2) 1.12(0.85,1.48) 0.43
+1995 AA 68(32.4) 65(30.9) 1.00(Reference)
+1995 AC 101(48.1) 98(46.7) 0.99(0.64,1.53) 0.95
+1995 CC 41(19.5) 47(22.4) 0.83(0.49,1.43) 0.51
+1995 A allele frequency 237(56.4) 228(54.3) 1.00(Reference)
+1995 C allele frequency 183(43.6) 192(45.7) 0.92(0.70,1.20) 0.53
OR: odds ratio; CI: confidence interval.
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was set at a nominal p-value o0.05 for all comparisons. SAS
version 9.1 (SAS Institute, Cary, NC) was used for all the
statistical tests.
’ RESULTS
The characteristics of the bladder cancer cases and healthy
control subjects are presented in Table 2. A univariate analysis
was performed and the results indicated that smoking
(p=0.01) was associated with bladder cancer (Table 2). No
significant difference was found between the bladder cancer
cases and healthy controls regarding sex or age (Table 2).
Regarding the tumor stage of the cases, 134 (63.8%) cases were
invasive (T2-T4) bladder cancer and 76 (36.2%) were super-
ficial (Tis-T1) bladder cancer. Regarding the tumor grades of
the cases, 65 (31.0%) cases were low grade (G1) bladder cancer
and 145 (69.0%) cases were high grade (G2+G3) bladder
cancer. The analysis of the histological types of the cases found
that 53 (25.2%) cases were nonpapillary bladder cancer and
157 (74.8%) were papillary bladder cancer.
The genotype frequencies were in agreement with the
Hardy-Weinberg equilibrium. The patients with bladder
cancer had a significantly higher frequency of the IL-22
-429 TT genotype (OR=2.04, 95% CI=1.19, 3.49; p=0.009) and
-429 T allele (OR=1.42, 95% CI=1.08, 1.87; p=0.01) than the
healthy control subjects (Table 3). The findings remained
significant after a Bonferroni correction was implemented.
When stratifying according to the stage of bladder cancer, we
found that superficial bladder cancer had a significantly
lower frequency of the IL-22 -429 TT genotype (OR=0.48,
95% CI=0.23, 0.98; p=0.04) (Table 4). When stratifying
according to the grade and histological type of bladder
cancer, we found no statistical association (Table 4). The
IL-22 +1046 T/A and IL-22 +1995 A/C gene polymorph-
isms were not associated with the risk of bladder cancer
(Table 3).
’ DISCUSSION
In this study, we investigated the association between
three common polymorphisms (-429 C/T, +1046 T/A and
+1995 A/C) of the IL-22 gene and the risk of bladder cancer
in a Chinese population. This prospective hospital-based
case-control study revealed that the IL-22 -429 C/T gene
polymorphism is associated with bladder cancer risk. To the
best of our knowledge, this is the first report in the literature
that evaluated the association between IL-22 gene poly-
morphisms and the risk of bladder cancer.
There is accumulating evidence that genetics plays a key role
in the susceptibility to and clinicopathologic characteristics of
Table 4 - Stratification analysis of the IL-22 -429 C/T polymorphism in bladder cancer cases.
CC
Cases (n=210) n (%) OR (95% CI) p
Tumor stage 210 68(32.4) 1(Reference)
Invasive 134 40(29.9) 0.92(0.59,1.44) 0.72
Superficial 76 28(36.8) 1.14(0.68,1.90) 0.62
Tumor grade 210 68(32.4) 1(Reference)
High 145 48(33.1) 1.02(0.67,1.57) 0.92
Low 65 20(30.8) 0.95(0.54,1.68) 0.86
Tumor histological type 210 68(32.4) 1(Reference)
Papillary 157 49(31.2) 0.96(0.63,1.47) 0.86
Nonpapillary 53 19(35.8) 1.11(0.61,2.00) 0.74
CT
Cases (n=210) n (%) OR (95% CI) P
Tumor stage 210 84(40.0) 1(Reference)
Invasive 134 46(34.3) 0.86(0.56,1.31) 0.48
Superficial 76 38(50.0) 1.25(0.79,1.99) 0.35
Tumor grade 210 84(40.0) 1(Reference)
High 145 55(37.9) 0.95(0.64,1.42) 0.80
Low 65 29(44.6) 1.12(0.67,1.85) 0.67
Tumor histological type 210 84(40.0) 1(Reference)
Papillary 157 66(42.0) 1.05(0.72,1.54) 0.80
Nonpapillary 53 18(34.0) 0.85(0.47,1.53) 0.59
TT
Cases (n=210) n (%) OR (95% CI) p
Tumor stage 210 58(27.6) 1(Reference)
Invasive 134 48(35.8) 1.30(0.84,2.01) 0.25
Superficial 76 10(13.2) 0.48(0.23,0.98) 0.04
Tumor grade 210 58(27.6) 1(Reference)
High 145 42(29.0) 1.05(0.67,1.65) 0.84
Low 65 16(24.6) 0.89(0.48,1.66) 0.72
Tumor histological type 210 58(27.6) 1(Reference)
Papillary 157 42(26.8) 0.97(0.62,1.52) 0.89
Nonpapillary 53 16(30.2) 1.09(0.58,2.05) 0.78
OR: odds ratio; CI: confidence interval.
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bladder cancer. Nine meta-analyses, each of which analyzed
between four and twenty-four studies, have provided evidence
that the following polymorphisms are associated with increased
bladder cancer risk: NQO1 Pro187Ser; PSCA rs2294008 (C>T);
XRCC1 Arg399Gln (especially in non-Asian populations);
MMP-2 -1306 C/T;MMP-9 -1562 C/T; XPD Lys751Gln; ERCC2
Arg156Arg; Asp312Asn; Lys751Gln; CCND1 G870A (which
may modulate the risk of bladder cancer in conjunction with
tobacco smoking); XPC A499V (in Caucasian populations);
CYP1A1 polymorphisms (especially the 11599G>C, 2455A>G,
3810T>C, and 113T>C polymorphisms in Asians); MDM2
SNP309T>G (among Caucasians) (28-36).
The mechanisms of action for the IL-22 -429 TT genotype
and T allele as risk factors for bladder cancer are still unclear.
IL-22 may play a role in controlling tumor growth and tumor
progression by inhibiting signaling pathways that promote
tumor cell proliferation, such as ERK1/2 and AKT phos-
phorylation (37). The IL-22 -429 C/T gene polymorphism has
been associated with the risks for various cancers. Genetic
polymorphisms and plasma levels of IL-22 contribute to the
development of non-small cell lung cancer (38). Recently, a
case-control study found that the IL-22 -429 C/T gene
polymorphism might be associated with the risk and
multifocality of papillary thyroid cancer (26). In 561 colon
cancer cases and 722 population controls, an association
study suggested that the rs1179251 SNP in IL-22 was
associated with the risk of colon cancer (23).
Several limitations to this study should be mentioned. First,
these results should be interpreted with caution because the
study subjects were Chinese; therefore, the study does not
permit extrapolation of the results to different ethnic popula-
tions. Second, this is a hospital-based case-control study.
Therefore, a selection bias could not be avoided and the
subjects may not be representative of the general population.
Third, the sample size of our study was relatively small and
may not have had adequate statistical power in detecting
significant differences. Finally, we did not evaluate the
relationships of the 3 common polymorphisms (-429 C/T,
+1046 T/A and +1995 A/C) to the plasma levels of IL-22,
which may potentially reflect the disease state of patients.
Therefore, the association of the IL-22 polymorphisms with
plasma levels of IL-22 should be further investigated.
In conclusion, to the authors’ knowledge, this is the first
report documenting that the IL-22 -429 C/T gene poly-
morphism is associated with bladder cancer risk. Additional
studies are required to confirm this finding.
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